FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim

Agency’s request will delay potential vasomotor symptoms launch by at least a year, but does not affect FDA review of the Effexor follow-on for major depressive disorder, Chief Medical Officer Stiles says.